search

Active clinical trials for "Squamous Cell Carcinoma of Head and Neck"

Results 1-10 of 1255

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Breast CancerColorectal Cancer4 more

A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.

Recruiting18 enrollment criteria

Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma...

Oral Squamous Cell Carcinoma

the purpose of this study is to assess the efficacy and safety of camrelizumab plus Docetaxel and Cisplatin as First-line Therapy in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients

Recruiting35 enrollment criteria

Dose Escalation Using Hypoxia-adjusted Radiotherapy

Head and Neck Squamous Cell Carcinoma

DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer. The study is aimed at assessing locoregional control, feasibility, and acceptable toxicity with such a strategy.

Recruiting18 enrollment criteria

A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment

Head and Neck Squamous Cell Carcinoma

The purpose of this study is to find out whether the fat ALT flap procedure is a safe and practical option for reducing neck morbidity in HNSCC patients following cancer treatment of the neck. Neck morbidity after radiation therapy and surgery includes difficulty swallowing, neck or shoulder pain, stiffness, swelling, or changes to the appearance of the treated area. In addition, the researchers will find out whether the study procedure is effective at reducing neck morbidity and improving quality of life after cancer treatment. The researchers will measure quality of life by having participants answer questionnaires.

Recruiting6 enrollment criteria

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors...

Non-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma4 more

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

Recruiting27 enrollment criteria

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

MelanomaUrothelial Carcinoma4 more

Safety study of RC198 in Subjects with Solid Tumors.

Recruiting69 enrollment criteria

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Non-Small Cell Lung CancerRenal Cell Carcinoma2 more

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Recruiting12 enrollment criteria

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell...

Oral Squamous Cell Carcinoma

TPF is still recommended as the preferred induction chemotherapy regimen for nonsurgical treatment of patients with LA HNSCC. Based on the KEYNOTE-048 study, all major guidelines recommend PD-1 monotherapy or PD-1 combined with chemotherapy as the new first-line standard treatment for patients with advanced HNSCC. The immunotherapy in operable LA HNSCC was also explored as neoadjuvant therapy due to the excellent data in advanced HNSCC. These explorations have also achieved good results. Therefore, this study aims to explore the pathological remission rate, the long-term benefit and safety of Tislelizumab combined with albumin paclitaxel, cisplatin and fluorouracil for locally advanced oral squamous cell carcinoma.

Recruiting23 enrollment criteria

Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer

Triple Negative Breast CancerRenal Cell Cancer2 more

The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1/Modi-1v vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC). Modi-1 will also be investigated in the neoadjuvant setting for patients with SCCHN undergoing curative intent surgical resection in combination with pembrolizumab versus the Modi-1 alone.

Recruiting62 enrollment criteria

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical...

Melanoma Stage IVHead and Neck Squamous Cell Carcinoma4 more

This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as donors.

Recruiting45 enrollment criteria
12...126

Need Help? Contact our team!


We'll reach out to this number within 24 hrs